The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101. Compensation available.

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact.  KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.

KAN-101 may help patients with celiac disease without interfering with the natural protective functions of the immune system. The goal of this study is to evaluate the safety and tolerability of single or multiple doses of the investigational drug KAN-101 in subjects with celiac disease. This study will also measure how the body responds to the study drug.


  • 18-70 years old
  • Biopsy-confirmed celiac disease
  • On a gluten-free diet for at least the last 12 months

See if you qualify:

Learn more at:

 About the Study Sponsor

Anokion SA, and its wholly owned subsidiaries Kanyos Bio, Inc. and Anokion, Inc., is a biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.

Assessment of KAN-101 in Celiac Disease (ACeD) Study Open